01

Litifilimab Improves Skin Disease Activity in Phase 2 CLE Trial

Litifilimab improved skin disease activity in a Phase 2 cutaneous lupus erythematosus trial, Medscape reports, marking a rare biologic signal in refractory CLE skin disease.